Premium
Toxic and therapeutic effects of EMTP in obesity
Author(s) -
Hollingsworth Dorothy R.,
Amatruda Thomas T.
Publication year - 1969
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1969104540
Subject(s) - placebo , medicine , fenfluramine , drug , weight loss , obesity , emtp , anesthesia , low calorie diet , pharmacology , physics , receptor , alternative medicine , electric power system , pathology , quantum mechanics , serotonin , power (physics)
EMTP (Fenfluramine), a new anorexigenic drug without properties that stimulate the central nervous system, was used as an ad;unct to an 800 calorie diet in a 120 day, double‐blind, randomized control study of 36 obese veterans. The greatest weight loss occurred in patients who were given the drug in Period 1 of the study and the least occurred in patients given placebo in Period 11. Although EMTP appeared more effective than the placebo, its results were not dramatic (nor statistically significant). The drug caused mild to moderately severe side effects in 25 of 36 patients whereas there were only mild complaints in 11 of 28 patients receiving the placebo. The large percentage of side effects may reflect the high dosage schedule in this drug trial. There was impotence in two men. Since most obesity drug evaluations are done in obese women, this effect might be missed.